title: Women living with drug abuse and HIV disease: drug abuse treatment access and secondary prevention issues.
abstract: In collaboration with the National Institute on Drug Abuse, the Health Resources and Services Administration is conducting a multisite, longitudinal study on issues of service needs, service utilization, and access to care for drug abusers with HIV. This article discusses access to drug abuse treatment and HIV secondary prevention for 116 women interviewed during the study's first year in five U.S. cities. Using interview data from 115 service providers in those same cities, it also discusses drug abuse treatment availability and barriers to service expansion for drug users with HIV. Study findings indicate that there are highly significant gaps between the drug abuse treatment services these women feel they need and those they have been able to receive; these were particularly pronounced for drug detoxification and residential and outpatient drug-free treatment. Women who used crack cocaine or injection drugs had particularly high levels of need for residential and outpatient drug abuse treatment, while women who use crack were found to have significantly less experience with the drug abuse treatment system than IDUs. HIV secondary prevention was also found to be a critical need for these women, many of whom were engaging in behaviors that place them at risk for reinfection, infection with other diseases, and transmission to others. Providers indicated that lack of funding was the major barrier to expanding services for this population; other barriers, such as lack of ancillary services and transportation, were also noted. Two positive findings were that many drug abuse treatment agencies in these cities provide a wide range of ancillary services and that many different kinds of agencies offer drug abuse treatment services.
authors.affiliation: Science and Epidemiology, BHRD, HRSA, Rockville, Maryland 20857, USA.
authors.forename: G
authors.initials: G
authors.lastname: Weissman
authors.forename: L
authors.initials: L
authors.lastname: Melchior
authors.forename: G
authors.initials: G
authors.lastname: Huba
authors.forename: G
authors.initials: G
authors.lastname: Smereck
authors.forename: R
authors.initials: R
authors.lastname: Needle
authors.forename: S
authors.initials: S
authors.lastname: McCarthy
authors.forename: A
authors.initials: A
authors.lastname: Jones
authors.forename: S
authors.initials: S
authors.lastname: Genser
authors.forename: L
authors.initials: L
authors.lastname: Cottler
authors.forename: R
authors.initials: R
authors.lastname: Booth
mesh_terms: D000293:Adolescent; D000328:Adult; D001519:Behavior; D002986:Clinical Trials as Topic; D016578:Crack Cocaine; D005260:Female; D015658:HIV Infections / Q000517:prevention & control / Q000523:psychology*; D006801:Humans; D008137:Longitudinal Studies; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000517:prevention & control / Q000523:psychology / Q000628:therapy; D019966:Substance-Related Disorders / Q000517:prevention & control / Q000523:psychology* / Q000628:therapy*; D014481:United States
chemical_list: D016578:Crack Cocaine